 COPENHAGEN, Denmark, Oct. 12, 2021 GLOBE NEWSWIRE -- Evaxion Biotech AS NASDAQ: EVAX Evaxion or the Company, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today a presentation by Emma Christine Jappe, PhD, Senior Scientist, Research Development, at the Immuno UK conference being held in London on October 13-14, 2021. 